Claims for Patent: 6,162,432

Summary for Patent: 6,162,432

Title:	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
Abstract:	Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
Inventor(s):	Wallner; Barbara P. (Weston, MA), Cooper; Kevin D. (Ann Arbor, MI)
Assignee:	Biogen, Inc. (Cambridge, MA) The Regents of The University of Michigan (Ann Arbor, MI)
Application Number:	08/466,465
Patent Claims:	1. A method of treating or providing prophylaxis for a skin condition characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis comprising the step of administering to a mammal an inhibitor of the CD2/LFA-3 interaction selected from the group of a CD2 polypeptide, an LFA-3 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog. 2. The method according to claim 1, wherein the condition is selected from the group consisting of atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, psoriasis and urticaria. 3. The method according to claim 1, wherein the skin condition is associated with UV damage. 4. The method according to claim 1, wherein the mammal is a human. 5. The method of claim 1, wherein said inhibitor is a CD2 polypeptide. 6. The method of claim 5, wherein said CD2 polypeptide is a soluble CD2 polypeptide. 7. The method of claim 1, wherein said inhibitor is an LFA-3 polypeptide. 8. The method of claim 7, wherein said LFA-3 polypeptide is a soluble LFA-3 polypeptide. 9. The method according to claim 8, wherein the inhibitor is a soluble LFA-3 polypeptide selected from the group of polypeptides consisting of AA.sub.1 -AA.sub.92 of SEQ ID NO:2, AA.sub.1 -AA.sub.80 of SEQ ID NO:2, AA.sub.50 -AA.sub.65 of SEQ ID NO:2, and AA.sub.20 -AA.sub.80 of SEQ ID NO:2. 10. The method of claim 8, wherein said soluble LFA-3 polypeptide is a soluble LFA-3 polypeptide fused to all or part of an immunoglobulin hinge and heavy chain constant region or portions thereof. 11. The method of claim 8, wherein said soluble LFA-3 polypeptide is LFA3TIP (SEQ ID NO:8). 12. The method of claim 1, wherein said inhibitor is an anti-CD2 antibody homolog. 13. The method according to claim 12, wherein the inhibitor is a monoclonal anti-CD2 antibody. 14. The method according to claim 12, wherein the inhibitor is a chimeric recombinant anti-CD2 antibody homolog. 15. The method according to claim 12, wherein the inhibitor is a humanized recombinant anti-CD2 antibody homolog. 16. The method according to claim 12, wherein the inhibitor is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a F(v) fragment and an intact immunoglobulin heavy chain of an anti-CD2 antibody homolog. 17. The method of claim 1, wherein said inhibitor is an anti-LFA-3 antibody homolog. 18. The method according to claim 17, wherein the inhibitor is a monoclonal anti-LFA-3 antibody. 19. The method according to claim 17 wherein the inhibitor is a chimeric recombinant anti-LFA-3 antibody homolog. 20. The method of claim 17, wherein said anti-LFA-3 antibody homolog is a humanized recombinant anti-LFA-3 antibody homolog. 21. The method according to claim 18, wherein the inhibitor is a monoclonal anti-LFA-3 antibody produced by a hybridoma selected from the group of hybridomas having Accession Nos. ATCC HB 10693 (1E6), ATCC HB 10694 (HC-1B11), ATCC HB 10695 (7A6), and ATCC HB 10696 (8B8). 22. The method according to claim 18, wherein the monoclonal anti-LFA-3 antibody is produced by a hybridoma selected from the group of hybridomas having Accession Nos. ATCC HB 10695 (7A6) and ATCC HB 10693 (1E6). 23. The method according to claim 17, wherein the inhibitor is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a F(v) fragment and an intact immunoglobulin heavy chain of an anti-LFA-3 antibody homolog. 24. The method according to claim 1, wherein the inhibitor is linked to one or more members selected from the group consisting of anti-LFA-3 antibody homologs, soluble CD2 polypeptides, cytotoxic agents and pharmaceutical agents. 25. The method according to claim 1, wherein the inhibitor is linked to one or more members selected from the group consisting of anti-CD2 antibody homologs, soluble LFA-3 polypeptides, cytotoxic agents and pharmaceutical agents. 26. The method according to claim 25, wherein the inhibitor is a polypeptide consisting of a soluble LFA-3 polypeptide linked to an immunoglobulin hinge and heavy chain constant region or portions thereof. 27. The method according to claim 26, wherein said polypeptide is LFA3TIP (SEQ ID NO:8). 28. A method of treating or providing prophylaxis for psoriasis comprising the step of administering to a mammal an inhibitor of the CD2/LFA3 interaction selected from the group of a CD2 polypeptide, an LFA-3 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog. 29. The method according to claim 28, wherein the skin condition is associated with UV damage. 30. The method according to claim 28, wherein the mammal is a human. 31. The method of claim 28, wherein said inhibitor is a CD2 polypeptide. 32. The method of claim 31, wherein said CD2 polypeptide is a soluble CD2 polypeptide. 33. The method of claim 28, wherein said inhibitor is an LFA-3 polypeptide. 34. The method of claim 33, wherein said LFA-3 polypeptide is a soluble LFA-3 polypeptide. 35. The method according to claim 34, wherein the inhibitor is a soluble LFA-3 polypeptide selected from the group of polypeptides consisting of AA.sub.1 -AA.sub.92 of SEQ ID NO:2, AA.sub.1 -AA.sub.80 of SEQ ID NO:2, AA.sub.50 -AA.sub.65 of SEQ ID NO:2, and AA.sub.20 -AA.sub.80 of SEQ ID NO:2. 36. The method of claim 33, wherein said soluble LFA-3 polypeptide is a soluble LFA-3 polypeptide fused to all or part of an immunoglobulin hinge and heavy chain constant region or portions thereof. 37. The method of claim 33, wherein said soluble LFA-3 polypeptide is LFA3TIP (SEQ ID NO:8). 38. The method of claim 28, wherein said inhibitor is an anti-CD2 antibody homolog. 39. The method according to claim 38, wherein the inhibitor is a monoclonal anti-CD2 antibody. 40. The method according to claim 38, wherein the inhibitor is a chimeric recombinant anti-CD2 antibody homolog. 41. The method according to claim 38, wherein the inhibitor is a humanized recombinant anti-CD2 antibody homolog. 42. The method according to claim 38, wherein the inhibitor is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a F(v) fragment and an intact immunoglobulin heavy chain of an anti-CD2 antibody homolog. 43. The method of claim 28, wherein said inhibitor is an anti-LFA-3 antibody homolog. 44. The method according to claim 43, wherein the inhibitor is a monoclonal anti-LFA-3 antibody. 45. The method according to claim 43, wherein the inhibitor is a chimeric recombinant anti-LFA-3 antibody homolog. 46. The method of claim 43, wherein said anti-LFA-3 antibody homolog is a humanized recombinant anti-LFA-3 antibody homolog. 47. The method according to claim 44, wherein the inhibitor is a monoclonal anti-LFA-3 antibody produced by a hybridoma selected from the group of hybridomas having Accession Nos. ATCC HB 10693 (1E6), ATCC HB 10694 (HC-1B11), ATCC HB 10695 (7A6), and ATCC HB 10696 (8B8). 48. The method according to claim 44, wherein the monoclonal anti-LFA-3 antibody is produced by a hybridoma selected from the group of hybridomas having Accession Nos. ATCC HB 10695 (7A6) and ATCC HB 10693 (1E6). 49. The method according to claim 43, wherein the inhibitor is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a F(v) fragment and an intact immunoglobulin heavy chain of an anti-LFA-3 antibody homolog. 50. The method according to claim 28, wherein the inhibitor is linked to one or more members selected from the group consisting of anti-LFA-3 antibody homologs, soluble CD2 polypeptides, cytotoxic agents and pharmaceutical agents. 51. The method according to claim 28, wherein the inhibitor is linked to one or more members selected from the group consisting of anti-CD2 antibody homologs, soluble LFA-3 polypeptides, cytotoxic agents and pharmaceutical agents. 52. The method according to claim 51, wherein the inhibitor is a polypeptide consisting of a soluble LFA-3 polypeptide linked to an immunoglobulin hinge and heavy chain constant region or portions thereof. 53. The method according to claim 52, wherein said polypeptide is LFA3TIP (SEQ ID NO:8). 54. A method of treating or providing prophylaxis for psoriasis comprising the step of administering to a mammal a composition comprising LFA3TIP (SEQ ID NO:8). 55. The method according to claim 54, wherein the mammal is a human.

Details for Patent 6,162,432

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036	January 30, 2003	6,162,432	2015-06-06

International Patent Family for US Patent 6,162,432

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9306866
United States of America	7323171
United States of America	6764681
United States of America	2006084107
United States of America	2004136987
United States of America	2002009449